Nuclera
PrivateLast Round
Series C
Extension
Jan 13, 2026
Est. Valuation
$17.09M
Total Funding Raised
$211.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Nuclera is a biotechnology company that develops automated protein prototyping systems to accelerate drug discovery workflows.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nuclera Comparables
Compare Nuclera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Biotage AB | 74% | |
| Thermo Fisher Scientific Inc. | 71% | |
| Evonetix | 69% |
Nuclera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Jan 13, 2026 | ||||
| Series C | Oct 16, 2024 | ||||
| Grant | Jun 6, 2024 | ||||
| Grant | Dec 6, 2023 | ||||
| Series B Extension | Jul 6, 2022 | ||||
Series B | Feb 2, 2022 |
Key People
Founding team and executive leadership
Nuclera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Amadeus Capital Partners | Series B |
| Verve Ventures | Series B Extension, Series C, Series C Extension, Series B |
| G. K. Goh Holdings Pte. Ltd. | Series C Extension, Series B, Series C |
| Future Planet Capital Regional | Series B |
| RT Ventures | Series A |
| Patient Square Capital | Series C, Series C Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 30, 2026
Launched nanodisc panel for GPCR screening and scale-up.
- Mar 29, 2026
Received an award at the One Nucleus Awards 2026.
Recent news
Latest coverage and updates
- hiresSep 22, 2026
Nuclera appoints Carl Raimond as Chief Executive Officer in United Kingdom and Massachusetts on Sep 22nd '26
- hiresSep 22, 2026
Nuclera hires Carl as CEO.
Nuclera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Nuclera's valuation, stock price, and market status.
Is Nuclera a public or private company?
Nuclera is a private company.
What is the current stock price of Nuclera?
Nuclera is a private company, so its shares have no public market price. Caplight tracks Nuclera's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nuclera worth (valuation)?
Nuclera's valuation is estimated at $17.1M based on funding round data.
Can I buy Nuclera stock?
Nuclera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nuclera's last funding round?
Nuclera's most recent funding round was Series C Extension on January 13, 2026.
Who are the main investors in Nuclera?
Key investors in Nuclera include RT Ventures, Meltwind Advisory, RT Partners, Elevage Medical Technologies.
Will Nuclera IPO soon?
No public IPO plans have been announced for Nuclera.
How can I track Nuclera secondary market activity?
Caplight tracks bids, offers, and trades in Nuclera's shares on secondary markets.